Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Inc. Investors

Core Viewpoint - Cytokinetics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the New Drug Application (NDA) for aficamten, which may have caused financial losses for investors [1][3]. Group 1: Class Action Details - The class action is on behalf of investors who purchased securities between December 27, 2023, and May 6, 2025, with a deadline for filing a lead plaintiff motion set for November 17, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Cytokinetics - The complaint alleges that during the class period, Cytokinetics made materially false and misleading statements about the NDA submission and approval timeline for aficamten [3]. - Specifically, the company indicated an expectation for FDA approval in the second half of 2025, based on a September 26, 2025 PDUFA date, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [3].